## Douglas J Conrad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6866612/publications.pdf

Version: 2024-02-01

34 papers 1,377 citations

430874 18 h-index 31 g-index

34 all docs

34 docs citations

times ranked

34

2038 citing authors

#	Article	IF	CITATIONS
1	Metagenomics and metatranscriptomics: Windows on CF-associated viral and microbial communities. Journal of Cystic Fibrosis, 2013, 12, 154-164.	0.7	142
2	Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME Journal, 2014, 8, 1247-1258.	9.8	114
3	Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung. Cell Host and Microbe, 2017, 22, 705-716.e4.	11.0	111
4	Cystic Fibrosis Therapy: A Community Ecology Perspective. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 150-156.	2.9	94
5	Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. International Journal of Mass Spectrometry, 2015, 377, 719-727.	1.5	90
6	Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME Journal, 2016, 10, 1483-1498.	9.8	88
7	The arachidonate 12/15 lipoxygenases. Clinical Reviews in Allergy and Immunology, 1999, 17, 71-89.	6.5	86
8	Ecological networking of cystic fibrosis lung infections. Npj Biofilms and Microbiomes, 2016, 2, 4.	6.4	77
9	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
10	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
11	Regulation of Human 12/15-Lipoxygenase by Stat6-Dependent Transcription. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 226-234.	2.9	53
12	Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. Genome Biology, 2019, 20, 226.	8.8	47
13	High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy. MSystems, 2020, 5, .	3.8	47
14	Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. Peerl, 2016, 4, e2174.	2.0	45
15	Niche partitioning of a pathogenic microbiome driven by chemical gradients. Science Advances, 2018, 4, eaau1908.	10.3	40
16	Molecular and Microbial Microenvironments in Chronically Diseased Lungs Associated with Cystic Fibrosis. MSystems, 2019, 4, .	3.8	23
17	Automated CT Staging of Chronic Obstructive Pulmonary Disease Severity for Predicting Disease Progression and Mortality with a Deep Learning Convolutional Neural Network. Radiology: Cardiothoracic Imaging, 2021, 3, e200477.	2.5	22
18	Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information. MBio, 2019, 10, .	4.1	20

#	Article	IF	Citations
19	Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis. Clinical Drug Investigation, 2020, 40, 105-117.	2.2	20
20	Microgranulomatous aspergillosis after shoveling wood chips: Report of a fatal outcome in a patient with chronic granulomatous disease. American Journal of Industrial Medicine, 1992, 22, 411-418.	2.1	19
21	Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenetics and Genomics, 2008, 18, 1095-1102.	1.5	19
22	Multidimensional Clinical Phenotyping of an Adult Cystic Fibrosis Patient Population. PLoS ONE, 2015, 10, e0122705.	2.5	19
23	Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome. International Journal of Molecular Sciences, 2021, 22, 12050.	4.1	14
24	Smartphone-Based pH Sensor for Home Monitoring of Pulmonary Exacerbations in Cystic Fibrosis. Sensors, 2017, 17, 1245.	3.8	13
25	Using Cystic Fibrosis Therapies for Non–Cystic Fibrosis Bronchiectasis. Clinics in Chest Medicine, 2016, 37, 139-146.	2.1	11
26	Complex and unexpected outcomes of antibiotic therapy against a polymicrobial infection. ISME Journal, 2022, 16, 2065-2075.	9.8	11
27	Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients. Journal of Cystic Fibrosis, 2021, 20, 91-96.	0.7	8
28	Characterizing Lung Disease in Cystic Fibrosis with Magnetic Resonance Imaging and Airway Physiology. PLoS ONE, 2016, 11, e0157177.	2.5	7
29	Bone Marrow Transplantation Rescues Monocyte Recruitment Defect and Improves Cystic Fibrosis in Mice. Journal of Immunology, 2022, 208, 745-752.	0.8	7
30	Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2017, 12, e0190061.	2.5	6
31	Plasmonic Sensing Studies of a Gas-Phase Cystic Fibrosis Marker in Moisture Laden Air. Sensors, 2021, 21, 3776.	3.8	3
32	Tensin 1 ( $\langle i \rangle$ TNS1 $\langle i \rangle$ ) is a modifier gene for low body mass index (BMI) in homozygous [ $\langle i \rangle$ F508del $\langle i \rangle$ ]CFTR patients. Physiological Reports, 2021, 9, e14886.	1.7	0
33	Draft Genome Sequence of the Multidrug-Resistant Strain Pseudomonas aeruginosa PA291, Isolated from Cystic Fibrosis Sputum. Microbiology Resource Announcements, 2021, 10, e0057221.	0.6	0
34	Metabolomics by mass spectrometry based molecular networking and spatial mapping. FASEB Journal, 2015, 29, 369.1.	0.5	0